Last updated on February 2018

Interventions for Reading Disabilities in NF1


Brief description of study

Neurofibromatosis Type 1 (NF1) is a common genetic disorder that is associated with a four times greater risk of learning disabilities, including reading disabilities, and a deficiency of neurofibromin - a protein important in a signaling pathway that regulates learning and memory. Our previous work (NS49096) demonstrated that school-age children with NF+RD can respond to standard phonologically-based reading tutoring originally developed to treat reading disability in the general population. Combining our work with that by other researchers suggesting that a medication (Lovastatin) may counteract the effects of the deficient neurofibromin, and possibly ameliorate learning disabilities in NF1, the investigator propose to examine the synergistic effects of medication plus reading tutoring.

Detailed Study Description

Neurofibromitosis Type 1 (NF1) is a common autosomal dominant neurocutaneous syndrome. The most common concern of NF1 is learning disabilities (LDs). Approximately half of children with NF1 have LDs, the most common of which are reading disabilities (RDs).The purpose of this research is to gain a deeper understanding of the characteristics and treatment of RDs in NF1.

The Investigator will evaluate three different groups (see list below) to determine if there are differential outcomes in these groups of children.with NF+RD.

  1. Reading tutoring program and a medication called Lovastatin
  2. Reading tutoring program and no Lovastatin (placebo)
  3. No reading (sham) tutoring and Lovastatin

Clinical Study Identifier: NCT02964884

Contact Investigators or Research Sites near you

Start Over

Laura E. Cutting

Vanderbilt University
Nashville, TN United States
  Connect »